Yun Zhong
Stock Analyst at Wedbush
(3.67)
# 796
Out of 5,113 analysts
46
Total ratings
50%
Success rate
9.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Outperform | $32 → $34 | $22.80 | +49.12% | 13 | Jan 23, 2026 | |
| RZLT Rezolute | Maintains: Neutral | $1 → $2 | $3.38 | -40.83% | 2 | Jan 8, 2026 | |
| WVE Wave Life Sciences | Maintains: Outperform | $20 → $33 | $13.25 | +149.06% | 3 | Dec 12, 2025 | |
| ASND Ascendis Pharma | Reiterates: Outperform | $220 | $233.65 | -5.84% | 3 | Nov 18, 2025 | |
| KROS Keros Therapeutics | Maintains: Neutral | $15 → $16 | $18.77 | -14.76% | 3 | Nov 6, 2025 | |
| IRD Opus Genetics | Initiates: Outperform | $8 | $2.81 | +184.70% | 1 | Oct 29, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Outperform | $70 → $86 | $82.30 | +4.50% | 3 | Oct 28, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $80 → $18 | $15.91 | +13.14% | 2 | Sep 30, 2025 | |
| PASG Passage Bio | Maintains: Outperform | $3 → $40 | $12.44 | +221.54% | 3 | Aug 13, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $28 | $6.03 | +364.34% | 1 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $8 | $4.00 | +100.00% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $3.44 | +132.56% | 1 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 | $3.63 | +781.54% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $28 | $5.02 | +457.77% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.72 | - | 2 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $14.29 | +11.97% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $25.27 | +82.03% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.49 | +1,932.11% | 1 | May 5, 2021 |
Sarepta Therapeutics
Jan 23, 2026
Maintains: Outperform
Price Target: $32 → $34
Current: $22.80
Upside: +49.12%
Rezolute
Jan 8, 2026
Maintains: Neutral
Price Target: $1 → $2
Current: $3.38
Upside: -40.83%
Wave Life Sciences
Dec 12, 2025
Maintains: Outperform
Price Target: $20 → $33
Current: $13.25
Upside: +149.06%
Ascendis Pharma
Nov 18, 2025
Reiterates: Outperform
Price Target: $220
Current: $233.65
Upside: -5.84%
Keros Therapeutics
Nov 6, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $18.77
Upside: -14.76%
Opus Genetics
Oct 29, 2025
Initiates: Outperform
Price Target: $8
Current: $2.81
Upside: +184.70%
Protagonist Therapeutics
Oct 28, 2025
Maintains: Outperform
Price Target: $70 → $86
Current: $82.30
Upside: +4.50%
MoonLake Immunotherapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $80 → $18
Current: $15.91
Upside: +13.14%
Passage Bio
Aug 13, 2025
Maintains: Outperform
Price Target: $3 → $40
Current: $12.44
Upside: +221.54%
Sagimet Biosciences
Aug 11, 2025
Initiates: Outperform
Price Target: $28
Current: $6.03
Upside: +364.34%
Aug 7, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $4.00
Upside: +100.00%
May 27, 2025
Initiates: Outperform
Price Target: $8
Current: $3.44
Upside: +132.56%
May 16, 2025
Reiterates: Outperform
Price Target: $32
Current: $3.63
Upside: +781.54%
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $5.02
Upside: +457.77%
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $4.72
Upside: -
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $14.29
Upside: +11.97%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $25.27
Upside: +82.03%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $0.49
Upside: +1,932.11%